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Introduction
Hepatic ischemia-reperfusion injury (IRI) represents the most significant physiopathological condition characterized by extensive inflammatory changes and is a major cause of mortality and morbidity after liver transplantation or major hepatic resections (1) (2) (3) . IRI consists of the primary injury from an ischemic condition and further injury once blood supply is restored (4) . The injury severity of the liver parenchyma ranges from moderately raised levels of serum aminotransferases to primary nonfunction or initial poor graft function, which is associated with many factors after liver transplantation, such as intrahepatic and/or extrahepatic nonanastomotic biliary strictures (5, 6) . IRI therapies are being extensively investigated due to a lack of available treatment in clinics to date (7) . Unfortunately, despite the urgent need for palliative therapy, clinical trials may not be initiated unless optimal treatment effects can be precisely evaluated.
Currently, pathological and biochemical examinations are widely used in both IRI diagnosis and treatment. Although pathological examination is regarded as the gold standard, it is an invasive procedure and provides only semiquantitative information. In contrast, a biochemistry test revealing serological changes is not able to show morphology or pathological changes. Thus, a method capable of visualizing inflammation during IRI in a noninvasive and quantitative manner could provide precise information for early diagnosis and monitoring therapeutic effects of the disease in preclinical research (8) (9) (10) .
Targeted ultrasound (US) imaging has been newly developed to characterize and measure biological processes at the cellular and molecular levels (11, 12) and combines the advantages of excellent sensitivity and specificity of contrast-enhanced ultrasound (CEUS). So far, targeted US imaging has shown good safety and accuracy in multiple preclinical trials (13, 14) , and it has been applied in human clinical research on neoangiogenesis with vascular endothelial growth factor receptor 2 (VEGFR2) targeted US imaging in various cancer types (15) . For targeted US imaging, gascontaining contrast microbubbles (MBs) based on liposomes are the most common probes functionalized with targeting ligands that specifically bind to particular molecular markers (11, 14) . Further, intracellular adhesion molecule 1 (ICAM-1) is known to be a major inflammatory molecule during IRI and is highly involved in the neutrophil rolling, adhering, diapedesis, and tissue infiltration during IRI (3). Considering its abundant expression at the hepatic sinusoidal endothelium at a very early stage after IRI, ICAM-1 could be an ideal target for designing targeted MBs. To quantify molecular ligand-attached contrast MBs, a typical destruction-replenishment regimen (Schematic diagram) was employed in most of the current preclinical studies on targeted US imaging (16) (17) (18) (19) . ICAM-1 targeted US imaging could be a promising quantitative technology enabling accurate detection and therapeutic monitoring IRI at the molecular level.
The present study aimed to precisely diagnose and monitor the therapy response of hepatic IRI with quantitative targeted US imaging.
Materials and Methods
All animals in the research were treated according to the guidelines issued by the Sun Yat-sen University Animal Care Committee. 
Preparation of MBs and in vitro specific binding experiment

Animal models
Male Sprague-Dawley rats weighing 270-300 g were acclimatized under the standard laboratory conditions at Sun Yat-sen University for 1 week. All animals were kept in a temperature-and humiditycontrolled room and divided into three groups to establish a quantitative targeted US imaging method: control group (n = 6), mild IRI group (n = 6), and moderate to severe IRI group (n = 12). In the IRI groups, the rats received hepatic IRI surgery as follows: rats were fasted 18 h before the experiments but were fed chow and water. Under pentobarbital sodium (30 mg/kg i.p.) anesthesia, the portal vein, hepatic artery, and bile duct were clamped to induce a complete ischemiic condition of the liver. After 20 or 30-40 min of the ischemia procedure, the clip around the vessels was removed to allow reperfusion, which led to mild IRI models or moderate to severe IRI models. In the control group, the rats underwent a sham operation: 30 min after anesthesia and laparotomy without clamping the portal vein, hepatic artery, and bile duct, the abdomens of the rats were closed. After 24 h of reperfusion or sham operation, CEUS was performed, and small amounts of blood (0.4 mL) and liver tissue were collected after the animals were killed (Figure 1 ). See Supporting Information (online) for details about the modeling evaluation. Targeted US imaging of ICAM-1 CEUS was performed according to the Supporting Information. Based on a clinical US imaging system (Logiq E9 digital premium ultrasound system, GE, Milwaukee, WI), images of the rat liver were collected by using a broadband ML6-15D high-frequency with imaging parameters as follows: frequency of 10 MHz, gain of 20-40 dB, image depth of 2-3 cm, acoustic output of 100%, dynamic range of 69 dB, and mechanical index of 0.07 at first porta hepatic plane of the liver section. Targeted US imaging was obtained via a destruction-replenishment approach (see Sigma plot): after 60 s of continuous imaging of sufficiently bond and free MBs, all MBs in the sector were destroyed by increasing the mechanical index from 0.07 to 0.24 for 1 s by setting a "flash" function. Subsequent postdestruction images lasted for 10 s to capture freely circulating MBs.
To demonstrate specific binding of MB ICAM-1 to the injured hepatic sinusoidal endothelium in vivo, two groups of animals were investigated: a control group (n = 3) and an IRI group (e.g. moderate to severe IRI models, n = 3). Then, 50 lL of MB CON in PBS with a bubble concentration of 2.0 9 10 7 bubbles/mL was injected via the tail vein. To allow clearance of MB CON , MB ICAM-1 with the same concentration and volume was applied to the rat 1 h after the previous injection. After the injection of each type of MB, a US imaging sequence using a destruction-replenishment approach was performed as described previously.
Establishment of quantitative targeted US imaging
A control group (n = 6), mild IRI group (n = 6), and moderate to severe IRI group (n = 12) were included. An offline analysis in random order was performed for all imaging data. A quantitative targeted US imaging signal from MBs that bonded to ICAM-1 was determined by using the CEUS quantitative analyzing software Sonamath (AmbitionT.C., Chongqing, China). Imaging of the regions of interest was performed using predestruction contrast frames representing both the attached and free MBs and postdestruction contrast frames representing only the freely circulating MBs. The imaging signal from the attached MBs was calculated by subtracting the postdestruction signal from the predestruction signal. The quantification of imaging signal was achieved by using normalized intensity differences (NIDs [%]). In other words, the ratio of the attached MBs imaging signal intensity to the total MBs imaging 
Monitoring of anti-inflammatory treatment
As for monitoring experiments, an additional six rats receiving IRI surgery (e.g. moderate to severe IRI rats) were treated with an anti-inflammatory drug. Briefly, andrographolide (1 mg/kg; Sigma, St. Louis, MO) dissolved in 2% DMSO was added in 0.1 mL saline and administered via intraperitoneal injections 2 h before the hepatic ischemia procedure and immediately before reperfusion. After 24 h of reperfusion, the in vivo quantitative targeted US imaging method was used to monitor treatment efficacy. The procedure was the same as described previously. Additionally, some regular examinations were used to evaluate anti-inflammatory treatment as described in the section on animal modeling.
Statistical analysis
All experiments were repeated at least three times, and the data were analyzed by using Student's t tests or one-way analysis of variance (SPSS software, version 13.0, SPSS Inc.). Unless otherwise specified, data were expressed as the mean AE standard deviation. A linear regression analysis was applied to access the correlation between ex vivo expression levels of ICAM-1 mRNA and in vivo NIDs. Moreover, the determination correlation coefficient (R 2 ) was calculated to access goodness of fit between these two variables. To determine the accuracy of the NID in treated animals, Pearson's linear analysis was applied between the actual intensity difference and the value estimated with use of the correlation equation. The correlation coefficient (r) was acquired to identify the correlation degree. A value of p < 0.05 was considered significant.
Results
Characterization of MB ICAM-1
According to the Dynamic Light Scattering measurements, the average diameter of MB ICAM-1 was 1.2 AE 0.1 lm, similar to that of MB CON (1.1 AE 0.2 lm). This result indicated that conjugation of ICAM-1 antibodies did not significantly affect particle size. In this study, MB ICAM-1 was prepared with use of an improved maleimide-thiol method, which increased the preparation efficiency ( Figure S1 ).
For the confocal laser scanning microscopy study, the DiI probe was encapsulated to make the MBs visible, and FITC-labeled secondary antibody was used to trace ICAM-1 antibody. As shown in Figure 2 , the red and green fluorescence almost overlapped, indicating successful conjugation of ICAM-1 antibody to MBs.
ICAM-1 targeted US imaging and quantitative analysis
To gain targeted CEUS imaging, MB ICAM-1 or MB CON was injected via the tail vein into the rats. On receiving MB ICAM-1 , a much stronger molecular US imaging signal was observed in the IRI group compared with that of the control group ( Figure 3A) . Additionally, a greater signal intensity in the IRI group was shown via administration of MB ICAM-1 compared with MB CON (Figure 3A) , confirming the specificity of MB ICAM-1 to IRI-liver . The NID was Figure 3B ).
ICAM-1 targeted US imaging was further applied to distinguish different degrees of IRI (mild IRI, moderate to severe IRI). After the administration of MB ICAM-1 , the imaging signal was strongest in the moderate to severe IRI group and weaker in the mild IRI group (Figure 4) . Consistently, the NID was significantly highest in the moderate to severe IRI group (37.14 AE 2.14) compared with that of the mild IRI group (22.34 AE 1.08, p = 0.002). The NIDs of both the moderate to severe IRI group and mild IRI group were much higher than that of control IRI (15.77 AE 0.91, p < 0.001 moderate to severe IRI group vs control group, p = 0.009 mild group vs control group) (Figure 4 ). With the subjection of ICAM-1 targeted US imaging, different levels of IRI were successfully identified. , which represented the determined degree of the NID relative to ICAM-1 mRNA expression, reached as high as 0.7434 ( Figure 5 ), and R 2 , analyzed with the conventional subtracted value, was only 0.3012. Apparently, the NID corresponding to ICAM-1 mRNA expression was reflected much more clearly in our improved method compared with the conventional way in which intensity difference was expressed as a simple subtraction. As the pathological result was regarded as the golden diagnosing standard, the accuracy of our quantitative data was verified by the significant correlation between the NID and molecular biological results, which laid the foundation for quantitative diagnosing and monitoring of IRI-liver.
Monitoring of anti-inflammatory treatment
The anti-inflammatory efficacy was estimated after andrographolide intraperitoneal treatment. CAM-1 ) and control microbubbles (MB CON ) in ischemia-reperfusion injury (IRI) rats and control rats. US signal after MB ICAM-1 in IRI liver was substantially higher than that in control liver and was significantly higher compared with MB CON in IRI liver and normal liver. (B) The normalized intensity differences (NIDs) were calculated as the ratio of subtraction using the destruction-replenishment method (n = 3, *p = 0.048, IRI group compared with control group after MB ICAM-1 administration). [Color figure can be viewed at wileyonlinelibrary.com]
at the mRNA level measured by RT-PCR indicated the severity of IRI. Indeed, ICAM-1 expression at the mRNA level decreased significantly (5.3 AE 2.9% vs 26.7 AE 15.6%, p = 0.008) ( Figure 6C ). Similarly, ICAM-1 immunohistochemical staining studies showed the same trend of mRNA levels. Specifically, ICAM-1 protein expression in treated animals was also weaker than that in IRI animals ( Figure 6F ). Additionally, pathological changes observed with the use of hematoxylin and eosin (H&E) staining in the IRI liver showed some unclear hepatic cord structures, sinusoidal congestion, and hepatocytes with karyopyknosis and swelling, and so on. In comparison, no obvious signs of these symptoms were identified in the treated IRI liver ( Figure 6E ). Suzuki's score on the basis of H&E staining was significantly lower in the treated group than that in the IRI group (0.93 AE 0.1 vs 2.2 AE 0.4, p < 0.001) ( Figure 6D ). All these results demonstrated the anti-inflammation effects of andrographolide for IRI by inhibiting ICAM-1 expression.
Monitoring of anti-inflammatory effect using targeted US imaging: After IRI surgery, animals in the treated group received targeted US imaging of ICAM-1 by injecting MB ICAM-1 via the tail vein. The ICAM-1 targeted US imaging signal ( Figure 7A ) in rats treated with andrographolide was weaker than that in the untreated animals ( Figure 7B ), which was consistent with other evidence of anti-inflammatory effects including serum indicators and pathological examinations after andrographolide treatment. Further quantitative analysis of targeted US imaging ( Figure 7D) using the NID was then conducted to show the anti-inflammatory efficacy of andrographolide as well. The NID decreased from 34.2 AE 6.6% to 17.7 AE 4.8% after treatment (p < 0.001), indicating less inflammation. ICAM-1 mRNA expression in the treated group was also detected, and then, the NID was estimated using the equation: Y = 1.11 X -9.5323 (where X and Y represent the NID and ICAM-1 mRNA expression, respectively). Finally, Pearson's linear analysis was applied in the treated group between NIDs estimated and obtained from targeted US imaging, respectively. The two quantitative data points were very close (correlation coefficient r = 0.828, p = 0.042), which strongly demonstrated the accuracy of our quantitative method using ICAM-1 US imaging to monitor antiinflammatory treatment in IRI animal models.
Discussion
IRI is known as a major cause of mortality for patients after liver transplantation (1-3) . Considering the available diagnosis methods for IRI with either invasive risk or nonspecific limitations (4, 5) , it is anticipated that a noninvasive and quantitative approach to access the severity of hepatic IRI would further encourage the robust studies in IRI treatment. Targeted US imaging meets such a need by the combination of a noninvasive modality and quantitative evaluation method at the molecular level. Hence, targeted US imaging possesses great potential for the early assessment of treatment effects. Although targeted US imaging has been used thus far in monitoring various diseases such as inflammatory diseases, cardiovascular diseases, and tumors (16, 20, 21) , it has not been investigated in hepatic IRI. In the present study, targeted US imaging was used for this disease as a quantificational and specific monitoring tool.
Because MBs remain within the vascular compartments due to their large size (several micrometers in general), the ideal targets for US imaging should be the molecules on the luminal surface (15) . For IRI, these molecules include ICAM-1, vascular adhesion molecule, and selectins, all of which play critical roles mediating the rolling of leukocytes on the vascular endothelium, leading to firm adhesion and diapedesis of leukocytes at sites of tissue injury and inflammation (22) (23) (24) (25) . Among the molecules, ICAM-1 is known as a major inflammatory molecule that reaches its highest expression level 24 hours after reperfusion, which is an appropriate time-frame for applying targeted US imaging (3, 23) . Therefore, targeted US imaging was conducted based on the detection of ICAM-1 US imaging signals during IRI. The technique that we proposed in the study could be extended to studies using other targets (such as vascular adhesion molecule, P-selectin) to evaluate IRI at various phases.
Because targeted contrast agents were the basis of targeted US imaging (14) , we designed an MB conjugating scFv ICAM-1 with an improved maleimide-thiol conjugation method. Compared with the conventional method, which fabricated MBs first and then linked antibodies (26, 27) , our approach, which linked antibodies first but fabricated MBs later, effectively reduced the loss of targeted MBs and thus enhanced the output. Details are shown in the Supporting Information [online].
Moreover, aiming at acquiring quantitative targeted US imaging signal of IRI, the destruction-replenishment method used in this study was improved. Several studies have used the traditional approach to define the quantitative targeted US imaging signal as the absolute subtraction value of imaging signal predestruction and postdestruction (conventional method) (16) (17) (18) (19) . However, slight deviations may occur because the absolute value was not able to exclude influences of tissue attenuation and system settings. A ratio of quantification could address those problems (28) . In Wang et al's study using an acute terminal ileitis model (28) , the intensity ratio was defined as the predestruction:postdestruction ratio of the imaging signal amplitudes (intensity ratio = image signal predestruction/image signal postdestruction) to quantify targeted US imaging (28) . In contrast, in the present study, the NID (NID = image signal before destruction -image signal postdestruction/image signal predestruction) was used to gain quantitative targeted US imaging. In a destruction-replenishment method, the exact targeted US imaging signal intensity should be the subtraction of the imaging signal after destruction from that before destruction (Sigma plot). Therefore, our method using the NID based on a signal intensity subtraction is believed to be more appropriate for quantitative imaging in the destruction-replenishment method, which is different from Wang et al's method using intensity ratio to emphasize magnification of the imaging signal from predestruction to postdestruction.
ICAM-1 NIDs were significantly higher in IRI rats (38.74 AE 15.08%) than in normal rats (10.08 AE 2.52%), which directly indicated more severe inflammatory changes in IRI rats. Considering that the quantitative targeted US imaging results in other studies often lacked evidence to show good consistency with the admitted golden standard, we further introduced a linear correlation analysis between the quantitative result (ICAM-1 NIDs) and pathological molecular level (ICAM-1 mRNA expression). As expected, the values of ICAM-1 NIDs varied against ICAM-1 mRNA expression linearly (R 2 = 0.7434, p < 0.001), which provided strong evidence of the reliability of the quantitative data based on targeted US imaging.
The use of our quantitative targeted US imaging method to monitor anti-inflammatory treatment was then evaluated in IRI rats. A drug, andrographolide, was confirmed to effectively reduce IRI inflammation. Andrographolide is a labdane diterpene lactone isolated from the leaves of the Andrographis paniculata plant, which has shown hepatocyte-protective and anti-inflammatory activities in many diseases (29) (30) (31) . However, its anti-inflammatory effect of IRI has never been demonstrated. In this study, we observed a significant anti-inflammatory effect of andrographolide on IRI animals as judged from serum test, biochemical test, pathological test, and targeted US imaging results. The anti-inflammatory mechanism of andrographolide for IRI may involve ICAM-1 regulation, but more details need to be explored. After treatment, ICAM-1 molecular images were first exported as a relatively quick and convenient qualitative result to monitor anti-inflammation effects. Subsequently, a quantitative analysis was applied to obtain a more precise result. ICAM-1 NID showed a 16.5% decrease (p < 0.001) in inflammation after treatment in IRI rats. Additionally, the data obtained from targeted US imaging and estimated from the previous equation in the treated group showed good accordance in a Pearson's linear analysis (r = 0.828, p < 0.001). Such quantitative data enabled monitoring of IRI treatment in a more objective and precise manner.
The following limitations should be noted for the present study. First, the quantitative approach using destructionreplenishment allowed separation of imaging signals from targeted and free MBs. A high mechanical index US pulse was conducted to destroy freely circulating MBs, which may lead to unwarranted biological consequences caused by MB-induced cavitation (15) . Second, the imaging approach was facilitated by a clinically available two-dimensional US transducer, which has a relatively limited field of view. In comparison, threedimensional quantification using phased-array threedimensional ultrasound transducers is more desirable to detect the spatial distribution of molecular marker expressions in targeted tissues for an improved imaging field (32, 33) . Third, the detection of ICAM-1 US molecular imaging presented limited information on phase of IRI. Finally, ICAM-1 mRNA levels, which were used to confirm the reliability of the NID, did not exactly reflect ICAM-1 protein expression on the cellular surface.
In conclusion, inflammation of IRI was quantitatively assessed in IRI rats with ICAM-1 targeted US imaging. Moreover, the accuracy and reliability of the improved quantitative targeted US imaging method were confirmed. Using this method, the anti-inflammatory treatment effect of andrographolide in rats with IRI was monitored successfully, which showed that this drug may provide a new IRI therapy. This study indicates that the new targeted US imaging strategy may facilitate clinical trials of IRI US diagnosis and therapeutic monitoring.
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Data S1: Supplemental Materials and Methods. : Hepatic IRI models of rats: (A) AST activity (n = 6, *p < 0.001 mild IRI group vs control group, # p < 0.001 moderate to severe IRI group vs mild IRI group, & p < 0.001 moderate to severe IRI group vs control group). (B) ALT activity (n = 6, *p = 0.001 mild IRI group vs control group, # p = 0.002 moderate to severe IRI group vs mild IRI group,
